Northeast Node of the Clinical Trials Network, Center for Technology and Behavioral Health, Geisel School of Medicine at Dartmouth College, 46 Centerra Parkway, Suite 315, NH, 03766, Lebanon, USA.
New Hampshire Citizen's Health Initiative, Institute for Health Policy and Practice, University of New Hampshire, 2 White Street, NH, 03301, Concord, USA.
Addict Sci Clin Pract. 2023 Apr 28;18(1):24. doi: 10.1186/s13722-023-00381-2.
National opioid-related overdose fatalities totaled 650,000 from 1999 to 2021. Some of the highest rates occurred in New Hampshire, where 40% of the population lives rurally. Medications for opioid use disorder (MOUD; methadone, buprenorphine, and naltrexone) have demonstrated effectiveness in reducing opioid overdose and mortality. Methadone access barriers disproportionally impact rural areas and naltrexone uptake has been limited. Buprenorphine availability has increased and relaxed regulations reduces barriers in general medical settings common in rural areas. Barriers to prescribing buprenorphine include lack of confidence, inadequate training, and lack of access to experts. To address these barriers, learning collaboratives have trained clinics on best-practice performance data collection to inform quality improvement (QI). This project sought to explore the feasibility of training clinics to collect performance data and initiate QI alongside clinics' participation in a Project ECHO virtual collaborative for buprenorphine providers.
Eighteen New Hampshire clinics participating in a Project ECHO were offered a supplemental project exploring the feasibility of performance data collection to inform QI targeting increased alignment with best practice. Feasibility was assessed descriptively, through each clinic's participation in training sessions, data collection, and QI initiatives. An end-of-project survey was conducted to understand clinic staff perceptions of how useful and acceptable they found the program.
Five of the eighteen health care clinics that participated in the Project ECHO joined the training project, four of which served rural communities in New Hampshire. All five clinics met the criteria for engagement, as each clinic attended at least one training session, submitted at least one month of performance data, and completed at least one QI initiative. Survey results showed that while clinic staff perceived the training and data collection to be useful, there were several barriers to collecting the data, including lack of staff time, and difficulty standardizing documentation within the clinic electronic health record.
Results suggest that training clinics to monitor their performance and base QI initiatives on data has potential to impact clinical best practice. While data collection was inconsistent, clinics completed several data-informed QI initiatives, indicating that smaller scale data collection might be more attainable.
1999 年至 2021 年,全美与阿片类药物相关的过量死亡人数总计达到 65 万。新罕布什尔州的死亡率最高,该州 40%的人口居住在农村地区。阿片类药物使用障碍(MOUD;美沙酮、丁丙诺啡和纳曲酮)已被证明可有效降低阿片类药物过量和死亡率。美沙酮的获取障碍不成比例地影响农村地区,纳曲酮的使用率也有限。丁丙诺啡的供应有所增加,而放宽的法规则减少了农村地区常见的一般医疗环境的障碍。开具丁丙诺啡的障碍包括缺乏信心、培训不足以及缺乏专家资源。为了解决这些障碍,学习合作组织已对诊所进行培训,以收集最佳实践绩效数据,为质量改进(QI)提供信息。该项目旨在探索培训诊所收集绩效数据并在诊所参与丁丙诺啡提供者的 ECHO 项目虚拟协作的同时启动 QI 的可行性。
参与 ECHO 项目的 18 家新罕布什尔州诊所获得了一项补充项目,该项目探索了收集绩效数据以告知 QI 的可行性,目标是与最佳实践更加一致。通过每个诊所参与培训课程、数据收集和 QI 举措,对可行性进行了描述性评估。在项目结束时进行了一项调查,以了解诊所工作人员对他们认为该项目的有用性和可接受性的看法。
参与 ECHO 项目的 18 家医疗保健诊所中有 5 家参加了培训项目,其中 4 家服务于新罕布什尔州的农村社区。所有 5 家诊所都符合参与标准,因为每家诊所都参加了至少一次培训课程,提交了至少一个月的绩效数据,并完成了至少一个 QI 举措。调查结果表明,虽然诊所工作人员认为培训和数据收集很有用,但在收集数据方面存在一些障碍,包括缺乏员工时间以及在诊所电子健康记录中难以标准化记录。
结果表明,培训诊所监测其绩效并根据数据制定 QI 计划有可能影响临床最佳实践。虽然数据收集不一致,但诊所完成了几个基于数据的 QI 举措,表明较小规模的数据收集可能更容易实现。